James C. Yao, M.D http://edmdrx.com ., Manisha H. Shah, M.D., Tetsuhide Ito, M.D., Ph.D., Catherine Lombard Bohas, M.D., Edward M. Wolin, M.D., Eric Van Cutsem, M.D., Ph.D., Timothy J. Hobday, M.D., Takuji Okusaka, M.D., Jaume Capdevila, M.D., Elisabeth G.E. De Vries, M.D., Ph.D., Paola Tomassetti, M.D., Marianne E. Pavel, M.D., Sakina Hoosen, M.D., Tomas Haas, Ph.D., Jeremie Lincy, M.Sc., David Lebwohl, M.D.D., Ph.D. For the RAD001 in Advanced Neuroendocrine Tumors, Third Trial Study Group: Everolimus for Advanced Pancreatic Neuroendocrine Tumors The prevalence and incidence of pancreatic neuroendocrine tumors are increasing1-3; these tumors represent approximately 1.3 percent of all cases of pancreatic cancer in incidence and 10 percent of cases in prevalence.1-3 Pancreatic neuroendocrine tumors are diagnosed at a late stage frequently, with approximately 65 percent of patients presenting with unresectable or metastatic disease; as a total result, these individuals have a poor prognosis.
Haug, M.D., Ph.D.1 The retractions came only months after BioMed Central, an open-access publisher owned by Springer, retracted 43 articles for the same reason. How can you really fake peer review? Moon, who studies medicinal plant life, had set up a straightforward procedure. He gave journals tips for peer reviewers for his manuscripts, providing them with names and e-mail addresses. But these addresses were ones he created, so the requests to review went to him or his colleagues directly. The fallout from Moon’s confession: 28 content articles in various journals published by Informa were retracted, and something editor resigned.